---
figid: PMC4976125__fphys-07-00342-g0005
figlink: /pmc/articles/PMC4976125/figure/F5/
number: F5
caption: ncRNAs as novel therapeutic strategies in cancer metabolism. Targeting cancer
  metabolism represents a novel resource to develop anti-cancer therapies. Now a days,
  there are different techniques developed to specifically modulate metabolic pathways,
  some of them are dedicated to silencing (LNA) or re-expressing (miRNA mimic) ncRNA
  transcripts (Phan et al., ). These systems can be delivered by intratumoral, intraperitoneal,
  and intravenous injections, through systemic adenovirus-associated virus (AAV),
  or in complexes with neutral lipid emulsions (Drakaki et al., ). In addition to
  these technologies, cholesterol-modified miRNAs (chol-anti-miRs) exhibit improved
  pharmacokinetics and antitumor efficacy. Human (1) The development of hepatocellular
  carcinoma (HCC) in persons who are persistently infected with hepatitis C virus
  (HCV) is a growing problem. A phase II trial of the LNA anti-miR-122 is being carried
  out for treatment of HCV infection (Lindow and Kauppinen, ). Xenograft mouse models
  (2) chol-anti-miR-221 effectively suppresses liver tumor growth (Park et al., ).
  (3) Systemic administration of miR-124 suppresses liver cancer growth through suppression
  of the IL6/STAT3 inflammatory pathway (Hatziapostolou et al., ). (4) AAV delivery
  of miR-26a or miR-122 suppresses MYC-driven liver carcinogenesis without affecting
  normal hepatocytes (Kota et al., ; Hsu et al., ). (5) Neutral lipid emulsions (NLE)
  to deliver let-7 which targets RAS and MYC oncogenes, as well as miR-34, reduces
  tumor size in lung cancer (Trang et al., ). (6) miR-101 and miR-376b are miRNAs,
  which negatively regulate the autophagy pathway (Frankel et al., ; Korkmaz et al.,
  ). Furthermore, overexpression of miR-101 suppressed tumor development and efficiently
  reduced tumor size in liver cancer (Su et al., ). (7) Over-expression of miR-101
  can effectively reduce tamoxifen-induced autophagy and enhance the sensitivity of
  breast cancer cells to tamoxifen treatment (Frankel et al., ). (8) Recombinant lentivirus
  administration of miR-30a (inhibitor of autophagy by down-modulating BECN1), can
  enhance sensitivity to imatinib cytotoxicity in chronic myeloid leukemia, increasing
  tumor cell apoptosis (Yu et al., ). In vitro (cell line models). (9) Up-regulation
  of miR-125a in cervical cancer (CC) models sensitized to paclitaxel by down-regulating
  STAT3 (Fan et al., ). (10) Re-expression of miR-30a can sensitize tumor cells to
  cisplatin via mediating autophagy in HeLa, MCF-7 and HepG2 (Zou et al., ). (11)
  Over-expression of miR-101 sensitized human lung carcinoma cells to radiation treatment
  (Yan et al., ).
pmcid: PMC4976125
papertitle: Insights into the Regulatory Role of Non-coding RNAs in Cancer Metabolism.
reftext: Fredy O. Beltr√°n-Anaya, et al. Front Physiol. 2016;7:342.
pmc_ranked_result_index: '124656'
pathway_score: 0.5226595
filename: fphys-07-00342-g0005.jpg
figtitle: ncRNAs as novel therapeutic strategies in cancer metabolism
year: '2016'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4976125__fphys-07-00342-g0005.html
  '@type': Dataset
  description: ncRNAs as novel therapeutic strategies in cancer metabolism. Targeting
    cancer metabolism represents a novel resource to develop anti-cancer therapies.
    Now a days, there are different techniques developed to specifically modulate
    metabolic pathways, some of them are dedicated to silencing (LNA) or re-expressing
    (miRNA mimic) ncRNA transcripts (Phan et al., ). These systems can be delivered
    by intratumoral, intraperitoneal, and intravenous injections, through systemic
    adenovirus-associated virus (AAV), or in complexes with neutral lipid emulsions
    (Drakaki et al., ). In addition to these technologies, cholesterol-modified miRNAs
    (chol-anti-miRs) exhibit improved pharmacokinetics and antitumor efficacy. Human
    (1) The development of hepatocellular carcinoma (HCC) in persons who are persistently
    infected with hepatitis C virus (HCV) is a growing problem. A phase II trial of
    the LNA anti-miR-122 is being carried out for treatment of HCV infection (Lindow
    and Kauppinen, ). Xenograft mouse models (2) chol-anti-miR-221 effectively suppresses
    liver tumor growth (Park et al., ). (3) Systemic administration of miR-124 suppresses
    liver cancer growth through suppression of the IL6/STAT3 inflammatory pathway
    (Hatziapostolou et al., ). (4) AAV delivery of miR-26a or miR-122 suppresses MYC-driven
    liver carcinogenesis without affecting normal hepatocytes (Kota et al., ; Hsu
    et al., ). (5) Neutral lipid emulsions (NLE) to deliver let-7 which targets RAS
    and MYC oncogenes, as well as miR-34, reduces tumor size in lung cancer (Trang
    et al., ). (6) miR-101 and miR-376b are miRNAs, which negatively regulate the
    autophagy pathway (Frankel et al., ; Korkmaz et al., ). Furthermore, overexpression
    of miR-101 suppressed tumor development and efficiently reduced tumor size in
    liver cancer (Su et al., ). (7) Over-expression of miR-101 can effectively reduce
    tamoxifen-induced autophagy and enhance the sensitivity of breast cancer cells
    to tamoxifen treatment (Frankel et al., ). (8) Recombinant lentivirus administration
    of miR-30a (inhibitor of autophagy by down-modulating BECN1), can enhance sensitivity
    to imatinib cytotoxicity in chronic myeloid leukemia, increasing tumor cell apoptosis
    (Yu et al., ). In vitro (cell line models). (9) Up-regulation of miR-125a in cervical
    cancer (CC) models sensitized to paclitaxel by down-regulating STAT3 (Fan et al.,
    ). (10) Re-expression of miR-30a can sensitize tumor cells to cisplatin via mediating
    autophagy in HeLa, MCF-7 and HepG2 (Zou et al., ). (11) Over-expression of miR-101
    sensitized human lung carcinoma cells to radiation treatment (Yan et al., ).
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - BRCA2
  - BRCA1
  - NLE1
genes:
- word: BRCA,
  symbol: BRCA
  source: bioentities_symbol
  hgnc_symbol: BRCA2
  entrez: '675'
- word: BRCA,
  symbol: BRCA
  source: bioentities_symbol
  hgnc_symbol: BRCA1
  entrez: '672'
- word: NLE
  symbol: NLE
  source: hgnc_prev_symbol
  hgnc_symbol: NLE1
  entrez: '54475'
chemicals: []
diseases: []
figid_alias: PMC4976125__F5
redirect_from: /figures/PMC4976125__F5
figtype: Figure
---
